Skip to main content
Clinical Trials/NCT06623981
NCT06623981
Recruiting
N/A

Testing the Effectiveness and Implementation of an Evidence-Based Maternal Depression Treatment in an Urban Pediatric Asthma Clinic

Children's National Research Institute1 site in 1 country60 target enrollmentOctober 15, 2024

Overview

Phase
N/A
Intervention
Enhanced Brief Interpersonal Psychotherapy
Conditions
Asthma in Children
Sponsor
Children's National Research Institute
Enrollment
60
Locations
1
Primary Endpoint
Maternal depressive symptoms
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

The goal of this clinical trial is to test the effectiveness and implementation of delivering Enhanced Brief Interpersonal Psychotherapy (IPT-B), an evidence-based maternal depression treatment, to mothers of children under the age of 18 in an urban pediatric asthma clinic. Researchers will compare Enhanced IPT-B and supplemented usual care (brief care coordination). The main questions the trial aims to answer are:

  1. Does Enhanced IPT-B decrease maternal depressive symptoms?
  2. Does Enhanced IPT-B improve child asthma management and health outcomes (exacerbations, symptoms, control)?
  3. What are the preliminary implementation outcomes of delivering Enhanced IPT-B in an urban pediatric asthma clinic?

Detailed Description

The purpose of the study is to determine the effectiveness and implementation of Brief Enhanced Interpersonal Psychotherapy (IPT-B), an evidence-based treatment for maternal depression, delivered in an urban pediatric asthma clinic. This study is a pilot Hybrid Type 1 Effectiveness-Implementation, single-blinded, prospective randomized controlled trial. A parallel two-group design will be used to evaluate the impact of the intervention (Enhanced IPT-B) among a sample of 48 Black mothers of children under the age of 18 with asthma. Mothers with PHQ-9 ≥ 8 will be identified in the asthma clinic through routine depression screening during the child's visit and recruited to participate in the study if they meet eligibility criteria. Following the informed consent process, mothers randomized to the intervention group will receive Enhanced IPT-B. Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual psychotherapy sessions carried out by a licensed mental health clinician within an 8-12-week timeframe. Mothers randomized to the comparison group will receive Supplemented Usual Care which involves short-term care coordination to access community mental health resources. Data on maternal mental health, child asthma management and outcomes, and child mental health will be collected from mothers and children at baseline, 3 months post-baseline, and 6 months post-baseline. Data on implementation outcomes will be collected from mothers and asthma clinic leadership and staff. Quantitative and qualitative data analysis strategies will be utilized to answer the research questions.

Registry
clinicaltrials.gov
Start Date
October 15, 2024
End Date
March 15, 2027
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Children's National Research Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Primary caregiver of the child with asthma seen at the community-based asthma clinic
  • Female (self-identified)
  • Black (self-identified)
  • ≥ 18 years of age
  • English-speaking
  • PHQ-9 ≥ 8 during standardized screening at the child with asthma's clinic visit
  • \<18 years old for the duration of the 6-month study period
  • Publicly insured
  • Physician-diagnosed persistent asthma

Exclusion Criteria

  • Acutely suicidal (high risk on the C-SSRS at child's asthma clinic visit)
  • Bipolar disorder or mania
  • Schizophrenia
  • Current substance abuse/dependence
  • Current serious physical intimate partner violence (IPV)
  • Lack of capacity to meaningfully participate in study procedures, as assessed by study staff during screening
  • Significant medical co-morbidity (e.g., disorders of the cardiorespiratory system, significant developmental delay, diabetes, seizure disorder, and sickle cell disease)
  • Enrolled in another intervention with a behavioral component and/or novel asthma therapeutics

Arms & Interventions

Enhanced IPT-B

Enhanced Brief Interpersonal Psychotherapy

Intervention: Enhanced Brief Interpersonal Psychotherapy

Supplemented Usual Care

Short-term care coordination

Intervention: Supplemented Usual Care

Outcomes

Primary Outcomes

Maternal depressive symptoms

Time Frame: T2 (3 months post-baseline)

≥ 50% reduction in depressive symptoms on the 9-item Patient Health Questionnaire (PHQ-9) at T2. The PHQ-9 score ranges from 0-27, with higher scores indicating more depressive symptoms. This variable will be dichotomized into 50% or greater reduction in depressive symptoms vs. less than 50% reduction in depressive symptoms from T1 to T2.

Secondary Outcomes

  • Clinically significant maternal depressive symptoms(T2 (3 months post-baseline))
  • Child asthma exacerbations(T3 (6 months post-baseline))
  • Child asthma symptoms(T2 (3 months post-baseline), T3 (6 months post-baseline))
  • Maintenance(T3 (6 months post-baseline))
  • Acceptability(T2 (3 months post-baseline))
  • Maternal anxiety symptoms(T2 (3-months post-baseline) and T3 (6months post-baseline))
  • Maternal PTSD symptoms(T2 (3 months post-baseline) and T3 (6 months post-baseline))
  • Child depressive symptoms(T2 (3 months post-baseline) and T3 (6 months post-baseline))
  • Feasibility(T2 (3 months post-baseline))
  • Child anxiety symptoms(T2 (3 months post-baseline) and T3 (6 months post-baseline))
  • Child asthma control(T2 (3 months post-baseline), T3 (6 months post-baseline))
  • Asthma management(T2 (3 months post-baseline))
  • Reach(T1 (Baseline))
  • Satisfaction(T3 (6 months post-baseline))
  • Staff-reported implementation outcomes(At the end of year 2)

Study Sites (1)

Loading locations...

Similar Trials